{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-Cell+Small+Lymphocytic+Lymphoma&page=4", "query": { "condition": "Refractory B-Cell Small Lymphocytic Lymphoma", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 564, "total_pages": 57, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-Cell+Small+Lymphocytic+Lymphoma&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Refractory+B-Cell+Small+Lymphocytic+Lymphoma&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-06T17:00:19.534Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01110135", "title": "Bendamustine Hydrochloride, Etoposide, Dexamethasone, and Filgrastim For Peripheral Blood Stem Cell Mobilization in Treating Patients With Refractory or Recurrent Lymphoma or Multiple Myeloma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Intraocular Lymphoma", "Nodal Marginal Zone B-cell Lymphoma", "Peripheral T-cell Lymphoma", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Refractory Multiple Myeloma", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Waldenström Macroglobulinemia" ], "interventions": [ { "name": "bendamustine hydrochloride", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "leukapheresis", "type": "PROCEDURE" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "flow cytometry", "type": "OTHER" }, { "name": "etoposide", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BIOLOGICAL", "PROCEDURE", "OTHER" ], "sponsor": "University of Washington", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 43, "start_date": "2010-08", "completion_date": null, "has_results": true, "last_update_posted_date": "2017-05-24", "last_synced_at": "2026-10-06T17:00:19.534Z", "location_count": 1, "location_summary": "Seattle, Washington", "locations": [ { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT01110135" }, { "nct_id": "NCT00066248", "title": "Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Tumor", "Central Nervous System Tumors", "Cachexia", "Leukemia", "Lymphoma", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Diseases", "Unspecified Childhood Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "cyproheptadine hydrochloride", "type": "DRUG" }, { "name": "megestrol acetate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of South Florida", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "20 Years", "sex": "ALL", "summary": "2 Years to 20 Years" }, "enrollment_count": 70, "start_date": "2003-06", "completion_date": "2007-08", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-10-06T17:00:19.534Z", "location_count": 40, "location_summary": "Oakland, California • Washington D.C., District of Columbia • Gainesville, Florida + 33 more", "locations": [ { "city": "Oakland", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Gainesville", "state": "Florida" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00066248" }, { "nct_id": "NCT05828589", "title": "A Study of BGB-21447, a Bcl-2 Inhibitor, in Mature B-Cell Malignancies", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Relapsed Non-Hodgkin Lymphoma", "Refractory Non-Hodgkin Lymphoma", "Relapsed Chronic Lymphocytic Leukemia", "Refractory Chronic Lymphocytic Leukemia", "Relapsed Follicular Lymphoma", "Relapsed Marginal Zone Lymphoma", "Relapse Diffuse Large B Cell Lymphoma", "Relapsed Small Lymphocytic Lymphoma", "Refractory Follicular Lymphoma", "Refractory Marginal Zone Lymphoma", "Refractory Small Lymphocytic Lymphoma", "Richter Transformation", "Refractory Diffuse Large B-cell Lymphoma", "Transformed Non-Hodgkin Lymphoma" ], "interventions": [ { "name": "BGB-21447", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "BeOne Medicines", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 51, "start_date": "2023-06-20", "completion_date": "2026-06-08", "has_results": false, "last_update_posted_date": "2026-07-14", "last_synced_at": "2026-10-06T17:00:19.534Z", "location_count": 7, "location_summary": "Washington D.C., District of Columbia • Iowa City, Iowa • Waukee, Iowa + 4 more", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Waukee", "state": "Iowa" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Mineola", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05828589" }, { "nct_id": "NCT00002908", "title": "Bryostatin 1 in Treating Patients With Relapsed Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia", "Lymphoma" ], "interventions": [ { "name": "bryostatin 1", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Barbara Ann Karmanos Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": null, "start_date": "1996-12", "completion_date": "2001-11", "has_results": false, "last_update_posted_date": "2013-04-05", "last_synced_at": "2026-10-06T17:00:19.534Z", "location_count": 1, "location_summary": "Detroit, Michigan", "locations": [ { "city": "Detroit", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00002908" }, { "nct_id": "NCT00376922", "title": "Music in Reducing Anxiety and Pain in Adult Patients Undergoing Bone Marrow Biopsy for Hematologic Cancers or Other Diseases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Chronic Myeloproliferative Disorders", "Leukemia", "Lymphoma", "Lymphoproliferative Disorder", "Multiple Myeloma and Plasma Cell Neoplasm", "Myelodysplastic Syndromes", "Myelodysplastic/Myeloproliferative Neoplasms", "Pain", "Precancerous Condition", "Psychosocial Effects of Cancer and Its Treatment" ], "interventions": [ { "name": "music therapy", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Wake Forest University Health Sciences", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 65, "start_date": "2006-06", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2017-05-30", "last_synced_at": "2026-10-06T17:00:19.534Z", "location_count": 1, "location_summary": "Winston-Salem, North Carolina", "locations": [ { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00376922" }, { "nct_id": "NCT05665530", "title": "A Study of PRT2527 as Monotherapy and in Combination With Zanubrutinib or Venetoclax in Participants With R/R Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Aggressive B-Cell Non-Hodgkin's Lymphoma (NHL)", "Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)", "Mantle Cell Lymphoma (MCL)", "Richter's Syndrome", "T-cell Lymphoma", "Diffuse Large B-cell Lymphoma (DLBCL)", "Marginal Zone Lymphoma", "Myeloid Malignancies", "Acute Myeloid Leukemia (AML)", "Chronic Myelomonocytic Leukemia (CMML)", "Myelodysplastic Syndrome (MDS)", "MDS/Myeloproliferative Neoplasm (MPN) Overlap Syndrome" ], "interventions": [ { "name": "PRT2527", "type": "DRUG" }, { "name": "Zanubrutinib", "type": "DRUG" }, { "name": "Venetoclax", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Prelude Therapeutics Incorporated", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 86, "start_date": "2023-09-12", "completion_date": "2026-01-21", "has_results": false, "last_update_posted_date": "2026-01-26", "last_synced_at": "2026-10-06T17:00:19.534Z", "location_count": 5, "location_summary": "Duarte, California • Bethesda, Maryland • Boston, Massachusetts + 2 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Bethesda", "state": "Maryland" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" }, { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT05665530" }, { "nct_id": "NCT07061951", "title": "Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Recurrent Chronic Lymphocytic Leukemia", "Recurrent Small Lymphocytic Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Small Lymphocytic Lymphoma" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Bone Marrow Biopsy", "type": "PROCEDURE" }, { "name": "Computed Tomography", "type": "PROCEDURE" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Mirdametinib", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 20, "start_date": "2026-05-27", "completion_date": "2030-02-01", "has_results": false, "last_update_posted_date": "2026-10-06", "last_synced_at": "2026-10-06T17:00:19.534Z", "location_count": 9, "location_summary": "Duarte, California • Irvine, California • Sacramento, California + 6 more", "locations": [ { "city": "Duarte", "state": "California" }, { "city": "Irvine", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07061951" }, { "nct_id": "NCT00003395", "title": "Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Leukemia", "Lymphoma", "Multiple Myeloma and Plasma Cell Neoplasm" ], "interventions": [ { "name": "arsenic trioxide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "17 Years", "maximum_age": null, "sex": "ALL", "summary": "17 Years and older" }, "enrollment_count": null, "start_date": "1998-04", "completion_date": "2000-03", "has_results": false, "last_update_posted_date": "2013-06-25", "last_synced_at": "2026-10-06T17:00:19.534Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00003395" }, { "nct_id": "NCT00265928", "title": "Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "bortezomib", "type": "DRUG" }, { "name": "rituximab", "type": "DRUG" }, { "name": "antibody therapy", "type": "PROCEDURE" }, { "name": "biological therapy", "type": "PROCEDURE" }, { "name": "enzyme inhibitor therapy", "type": "PROCEDURE" }, { "name": "monoclonal antibody therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "University of Virginia", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": null, "completion_date": null, "has_results": false, "last_update_posted_date": "2008-01-28", "last_synced_at": "2026-10-06T17:00:19.534Z", "location_count": 1, "location_summary": "Charlottesville, Virginia", "locations": [ { "city": "Charlottesville", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT00265928" }, { "nct_id": "NCT04434196", "title": "A Safety and Preliminary Efficacy Study of CC-99282 in Combination With Obinutuzumab in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoma, Non-Hodgkin" ], "interventions": [ { "name": "CC-99282", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Celgene", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 16, "start_date": "2020-12-21", "completion_date": "2024-05-21", "has_results": false, "last_update_posted_date": "2024-07-25", "last_synced_at": "2026-10-06T17:00:19.534Z", "location_count": 4, "location_summary": "Boston, Massachusetts • Columbus, Ohio • Portland, Oregon + 1 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Columbus", "state": "Ohio" }, { "city": "Portland", "state": "Oregon" }, { "city": "Dallas", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT04434196" } ] }